What Khandelwal Laboratories does

Khandelwal Laboratories Pvt. Ltd. (KLab) is an 80-year-old, privately held Indian pharmaceutical company headquartered in Mumbai that develops, manufactures, and markets patented formulations, Novel Drug Delivery Systems (NDDS), specialty Active Pharmaceutical Ingredients (APIs), and chiral intermediates. It operates three WHO-GMP approved facilities in Thane (oncology formulations and APIs, ISO 9001:2008 certified), Rudrapur (separate Beta-Lactam and non-Beta-Lactam tablet blocks built to cGMP/EU GMP standards, 1 billion tablets/year combined capacity), and Dadra (injectables), and protects its technology stack with more than 222 patents granted or pending around NDDS, Nanotechnology, Dendrimers, and Chiral Chemistry.

KLab is the pioneer of oncology formulations in India, having introduced Cyclophosphamide and Bleomycin to the domestic market, and now markets more than 30 oncology drugs spanning liquid injections, sterile dry powder, lyophilized injections, tablets, and capsules. Beyond oncology, it runs a broad prescription portfolio across antibiotics, anti-infectives, pain and spasm management, anti-diabetics, anti-hypertensives, and tonics (the non-oncology branded franchise was sold to Aurobindo Pharma in January 2026 for ₹325 crore), a specialty API business supplying both captive and third-party demand, a contract manufacturing service for more than 10 Indian and multinational pharma companies, and an exclusive India distribution portfolio of in-licensed international brands in devices, diagnostics, dermocosmetics, and women's health.

The company monetizes primarily through branded formulation sales to a field force of 425 medical representatives covering 250,000 doctors, 100,000 pharmacies and 1,500 stockists across 21 zones and 450 territories, supplemented by contract manufacturing fees, API sales, and in- and out-licensing royalties. International revenues flow from exports and out-licensing to more than 20 countries across South-East Asia, Asia Pacific, Africa, Central America, the Caribbean, and parts of the Middle East and South America, supported by 400+ product registrations. Leadership is held by Managing Director Sanjeev Khandelwal, and the business has no disclosed institutional investor or public listing.

Name

Khandelwal Laboratories

Legal name

Khandelwal Laboratories Pvt. Ltd.

Website

https://khandelwallab.com

Company type

Private

Founded year

1945

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Khandelwal Laboratories (KLab) is a privately held Indian pharmaceutical company founded in 1945 that develops and manufactures patented oncology formulations, specialty APIs, and Novel Drug Delivery Systems across three WHO-GMP facilities, serving Indian prescribers, emerging-market partners, and contract manufacturing clients.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Specialty Pharmaceutical Distributors (HLAIAJAB), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Pharmaceutical formulations
• Oncology drugs
• Active pharmaceutical ingredients
• Contract manufacturing
• Novel drug delivery

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Formulation Sales: Manufacturing and sale of patented pharmaceutical formulations across therapeutic areas including oncology, antibiotics, pain management, and anti-infectives to doctors, pharmacies and through stockists across India
2. API Sales: Manufacturing and sale of Active Pharmaceutical Ingredients including specialty APIs (Oncology and non-Oncology) for own consumption and open market
3. Contract Manufacturing: Contract manufacturing on P2P (Payment to Process) and Loan Licensing basis for various Indian pharmaceutical companies and multinational corporations. Currently serves more than 10 companies.
4. Licensing (In-licensing and Out-licensing): In-licensing of unique high performance life science products for Indian market and out-licensing products to companies in India and developing countries such as Latin America, South-East Asia, Africa, CIS

Go-to-market motion2 records

Distribution channels3 records

Marketing channels1 record

Core offering

Khandelwal Laboratories (KLab) researches, develops, manufactures, and markets patented pharmaceutical formulations, Novel Drug Delivery Systems (NDDS), and niche Active Pharmaceutical Ingredients (APIs). The company's core offerings span oncology formulations (over 30 cancer drugs), general pharmaceutical formulations across multiple therapeutic areas (antibiotics, anti-diabetics, anti-hypertensives, anti-infectives, etc.), specialty APIs, contract manufacturing services, and in-licensed global brands marketed in India.

Product overview

Khandelwal Laboratories (KLab) is a privately owned Indian pharmaceutical company founded in 1945, specializing in research, development, manufacturing, marketing, and licensing of patented pharmaceutical formulations, NDDS (Novel Drug Delivery Systems), niche APIs, and chiral intermediates. The company operates three WHO-GMP approved manufacturing facilities located in Thane (oncology and API), Rudrapur (tablets), and Dadra (injectables). Its core product portfolio spans oncology formulations (over 30 drugs including Temozol and Mamazol), general pharmaceuticals across 12 therapeutic segments, and specialty APIs. The company also provides contract manufacturing services and manages a global branding program through in-licensing arrangements with international partners for products including Indermil Flexifuse, TriPore, Radiocare, TruScreen, and Opko Health products. KLab's products reach 250,000 doctors, 100,000 pharmacies, and 1,500 stockists across India.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncology Formulations Portfolio A portfolio of over 30 oncology drugs including Temozol (temozolamide), Mamazol (letrozole), Cyclophosphamide, and Bleomycin, available as liquid injections, sterile dry powder injections, lyophilized injections, tablets, and capsules. Targeted at oncologists and cancer patients across India and 20+ countries.
• Pharmaceutical Formulations Portfolio Broad portfolio of pharmaceutical formulations spanning therapeutic areas including antibiotics, antimicrobials, anti-spasmodics, muscle relaxants, anti-diabetics, anti-hypertensives, topical antibacterials, anthelmintics, cough syrups, antioxidants, calcium preparations, and tonics. Targeted at doctors, pharmacies, and stockists across India.
• Active Pharmaceutical Ingredients (APIs) Specialty APIs (both oncology and non-oncology) manufactured for in-house consumption and open market sale. Includes niche and chiral intermediates developed using proprietary Chiral Chemistry capabilities.
• Contract Manufacturing Services Contract manufacturing on P2P (Purchase to Pay) and Loan Licensing basis for Indian pharmaceutical companies and multinational corporations. Currently serves more than 10 companies.
• International Export Products Oncology and general formulations exported to more than 20 countries across South-East Asia, Asia Pacific, Africa, Central America, and Caribbean Islands through outright private markets, tenders, licensing, and contract manufacturing channels.
• Indermil Flexifuse Topical adhesive device for tissue sealing, licensed exclusively from Connexicon Medical Ltd. (Ireland) for the Indian market. Targeted at hospitals and surgical specialists.
• TriPore Advanced synthetic bone graft biomaterial, licensed exclusively from Orthogem Limited (UK) for the Indian market. Targeted at orthopedic surgeons and hospitals.
• Radiocare Dermatological prescription product, licensed exclusively from Cantabria Labs (Spain) for the Indian market. Targeted at dermatologists.
• Isrene Gel and Pelvic Gel Pharmaceutical and diagnostic products, licensed exclusively from Opko Health (Spain) for the Indian market.
• TruScreen Real-time cervical screening tool for detection of precancerous and cancerous cervical cells, licensed exclusively from Truscreen (New Zealand) for the Indian market. Targeted at gynecologists and diagnostic centers.
• NDDS and Novel Drug Delivery Platforms Proprietary drug delivery platforms incorporating Nanotechnology, Dendrimers, and Chiral Chemistry with more than 222 patents granted/pending. Marketed in India and out-licensed to companies in developing countries.

Quantifiable outcome

• 450 million uncoated/coated tablets, 15 million capsules, 60 million ampoules, 75 million vials annual production capacity at Thane plant
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Connexicon Medical Ltd.coreOEM/ Whitelabel/ Licensing PartnerIrish company specializing in tissue adhesives and sealants for topical and internal applications. KLab has exclusive rights for Indermil Flexifuse (topical adhesive device) for the Indian market.
• Orthogem LimitedcoreOEM/ Whitelabel/ Licensing PartnerUK-based biomaterials company manufacturing advanced Synthetic Bone Graft material, TriPore. KLab has exclusive arrangement to market TriPore in India.
• Cantabria LabscoreOEM/ Whitelabel/ Licensing PartnerSpanish group (formerly IFC) and leading brand in dermatological prescription in Europe. KLab has exclusive arrangement to market Radiocare in India.
• Opko HealthcoreOEM/ Whitelabel/ Licensing PartnerSpanish multinational pharmaceutical and diagnostics company owned by Phillip Frost. KLab has exclusive arrangement to market Isrene Gel and Pelvic Gel in India.
• TruscreencoreOEM/ Whitelabel/ Licensing PartnerNew Zealand-based company with TruScreen, a real-time cervical screening tool for detection of precancerous and cancerous cervical cells. KLab has exclusive arrangement to market TruScreen in India.

Scale indicators12 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Cipla: One of India's largest pharmaceutical companies with a significant oncology and specialty franchise. Comparable in operating geography and field-force-driven India distribution model, though much larger and more diversified than KLab.
• Dr. Reddy's Laboratories: Leading Indian pharma with oncology, APIs, and specialty formulations businesses. Comparable in product mix (oncology formulations + APIs) and global regulatory footprint, but at materially larger scale.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company with a broad specialty and oncology portfolio. Comparable in oncology formulations and APIs at India scale, though substantially larger and globally diversified.
• Fresenius Kabi India: Global specialty pharma subsidiary with Indian operations focused on injectable oncology and clinical nutrition. Comparable in injectable oncology manufacturing and Indian hospital-channel distribution.

Regional players

• Glenmark Pharmaceuticals: Indian-headquartered specialty and generics pharma with oncology and proprietary drug delivery platforms. Comparable in India-focused specialty franchise and innovation-driven formulations, with greater emerging-market footprint.

Direct peers

• Aurobindo Pharma: Large Indian generics and specialty pharma company that acquired KLab's non-oncology business in January 2026. Comparable as a vertically integrated Indian pharma with API, formulation, and contract manufacturing operations.
• Natco Pharma: Indian specialty pharmaceutical company with a strong oncology franchise. Directly comparable to KLab as an India-headquartered oncology-focused mid-cap pharma with API and formulation capabilities and international exports.
• Bharat Serums and Vaccines: Indian specialty biopharmaceutical company focused on critical care, oncology injectables, and biologicals. Directly comparable to KLab in oncology injectable formulations and lyophilized products produced at the Thane plant.
• Emcure Pharmaceuticals: Indian pharma company with oncology, gynecology, and contract manufacturing businesses. Comparable as an Indian mid-cap with manufacturing services, international presence, and oncology formulations.
• Shilpa Medicare: Indian specialty pharmaceutical and API manufacturer with oncology, transdermal, and complex generics focus. Comparable as a mid-cap Indian company with proprietary drug delivery technology and API capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

• Xx.com/khandelwallab

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Khandelwal Laboratories